# A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

> **NCT01276639** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 901 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** CP-690,550
- **DRUG:** CP-690,550
- **DRUG:** Placebo/CP-690,550
- **DRUG:** Placebo/CP-690,550

## Key facts

- **NCT ID:** NCT01276639
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 901 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01276639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01276639, "A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01276639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*